Transplant complications: Difference between revisions
ClaireLewis (talk | contribs) No edit summary |
ClaireLewis (talk | contribs) No edit summary |
||
Line 23: | Line 23: | ||
*[[Lung transplant complications]] | *[[Lung transplant complications]] | ||
*[[Pancreas transplant complications]] | *[[Pancreas transplant complications]] | ||
*More severe or opportunistic infections due to immunocompromise | |||
==See Also== | ==See Also== | ||
*[[Immunocompromised antibiotics]] | |||
==External Links== | ==External Links== |
Revision as of 19:51, 5 September 2016
Background
- Transplanted organ frequency: kidney > liver > heart > lung > pancreas > other (combined and intestines)
- Most transplant patients require lifelong immunosuppression
Epidemiology
- Types of presentations
- Infection (39%)
- Noninfectious GI/GU pathology (15%)
- Dehydration (15%)
- Electrolyte disturbances (10%)
- Cardiopulmonary pathology (10%)
- Injury (8%)
- Rejection (6%)
- Acute graft-versus-host disease occurs in 20% to 80% of patients post-hematopoietic stem cell transplantation (HSCT); rarely occurs in solid organ transplant [1]
Immunosuppressant Medications
- Balance between immune suppression, rejection and susceptibility to infection
- Typical regimen includes: calcineurin inhibitor + antimetabolite + steroid
- Calcineurin inhibitor
- Steroids
- +/- Antimetabolite
Types
- Graft-vs-host disease
- Kidney transplant complications
- Liver transplant complications
- Heart transplant complications
- Lung transplant complications
- Pancreas transplant complications
- More severe or opportunistic infections due to immunocompromise
See Also
External Links
References
- ↑ Tintinalli's